Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

Abstract excerpt

Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and Leishmania infantum , is one of the major parasitic diseases worldwide. There is an urgent need for new drugs to treat VL, because current therapies are unfit for purpose in a resource-poor setting. Here, we describe the development of a preclinical drug candidate, GSK3494245/DDD01305143/compound 8, with potential to treat this...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Research on Leishmaniasis Studies
• Share to Synthesis and Biological Evaluation
• Share to Trypanosoma species research and implications